Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity …
Pipeline - Cingulate Inc
Cingulate currently has three (3) product candidates, CTx-1301 (dexmethylphenidate), CTx-1302 (dextroamphetamine) and CTx-2103 (anxiety) in the pipeline. All three therapies utilize …
Press Releases - Cingulate Inc
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE …
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in …
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric …
May 20, 2025 · Last month Cingulate announced positive top-line results of a high dose (50-mg) food effect study for CTx-1301, with the primary endpoints establishing that it can be taken …
Dr. Alice Mao, MD - Advisors | Cingulate Inc
The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent …
Jul 29, 2025 · With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop …
Events & Presentations - Cingulate Inc
Jun 16, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx …
0001493152-24-004061 | 8-K | iXBRL Viewer | Cingulate INC
Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).
Cingulate to Participate in Benzinga All Live Access Event
The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.